ACRS
Aclaris Therapeutics Inc
4.30$
-2.7%
vs. previous close
Closing price · As of: Oct 5, 2026
Statements
Cash Flow
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -264.6% | -38.5% | -868.0% | -445.5% | 506.2% | -97.0% | -897.4% | -562.4% | -331.4% | -1,014.0% | -909.3% | -1,218.4% | -755.1% | |
| 2.4% | 1.3% | 10.1% | 8.7% | 4.6% | 1.6% | 8.8% | 6.4% | 3.3% | 7.9% | 5.1% | 6.6% | 5.1% | |
| 64.1% | 7.2% | 87.1% | 105.0% | 69.1% | 31.0% | 243.0% | 172.4% | 86.7% | 225.9% | 160.2% | 164.0% | 141.8% | |
| 82.4% | – | – | – | – | – | – | – | – | – | – | – | – | |
| -34.1% | 75.5% | -375.6% | -169.2% | 589.1% | -10.8% | -133.0% | 42.7% | 18.6% | 249.9% | -81.4% | -87.2% | 9.8% | |
| 0.9% | 2.5% | 5.6% | 0.5% | 0.0% | 388.8% | 60.2% | 1.2% | 0.7% | 1.9% | 0.7% | 3.6% | 1.4% | |
| 350.5% | 43.0% | 702.0% | -24.4% | 64.3% | -963.2% | 1,314.0% | 284.0% | 419.2% | 800.7% | -1,549.7% | 630.0% | 42.9% | |
| -1.1% | 0.6% | -2.3% | -0.4% | -0.2% | -3.6% | -18.9% | -0.5% | 8.3% | -12.5% | – | – | – | |
| -0.9% | 0.3% | -2.3% | -0.4% | 0.5% | 809.7% | -18.9% | -0.5% | -92.3% | -195.7% | 2,894.8% | 5.6% | 636.3% | |
| 85.0% | 4.8% | -168.3% | -470.2% | 571.0% | -250.6% | 397.7% | -278.8% | -4.4% | -409.0% | 435.9% | -582.8% | -75.9% | |
| -265.5% | -41.0% | -873.6% | -445.0% | 506.2% | -485.8% | -957.6% | -563.5% | -332.1% | -1,015.8% | -909.3% | -1,222.7% | -756.5% |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: October 5, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.